Palatin Technologies (LTS:0KF3) Short-Term Debt: $ Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0KF3 Palatin Technologies Inc LTS:0KF3
45 GF Score
Price $11.14
GF Value $51.03
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Palatin Technologies Short-Term Debt?

Palatin Technologies LTS:0KF3 +9.54% 45 Short-Term Debt is $ Mil as of Mar. 2026. GuruFocus rates LTS:0KF3 with a GF Score™ of 45/100 and a GF Value™ of $51.03 (Possible Value Trap). The stock has 5 warning signs investors should review.

Palatin Technologies's Short-Term Debt for the quarter that ended in Mar. 2026 was $ Mil.

Palatin Technologies Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Palatin Technologies Short-Term Debt Related Terms

Palatin Technologies Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Palatin Technologies's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palatin Technologies Short-Term Debt Chart

Palatin Technologies Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.00 0.00 0.00 -

Palatin Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
LTS:0KF3
45GF Score
Palatin Technologies Inc LTS:0KF3
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $ Mil mean?
Palatin Technologies (LTS:0KF3) has a Short-Term Debt of $ Mil as of Mar. 2026.
Is Palatin Technologies' Short-Term Debt too high?
Palatin Technologies' current Short-Term Debt is $ Mil. Overall, Palatin Technologies has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Palatin Technologies' Short-Term Debt compare to BIVI and NCEL?
Palatin Technologies' Short-Term Debt of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Palatin Technologies's current Short-Term Debt is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palatin Technologies stock overvalued right now?
Based on GuruFocus' analysis, Palatin Technologies (LTS:0KF3) is currently considered Possible Value Trap. The stock's GF Value™ is $51.03, compared to a current price of $11.14 — trading 78.2% below its estimated fair value. The current Short-Term Debt is $ Mil. Palatin Technologies' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Palatin Technologies (LTS:0KF3), the current Short-Term Debt is $ Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Palatin Technologies (LTS:0KF3) Overvalued in 2026?

Based on GuruFocus' analysis, Palatin Technologies stock appears to be undervalued. The current stock price of $11.14 is trading 78.2% below its estimated GF Value™ of $51.03. GuruFocus considers Palatin Technologies to be Possible Value Trap.

Key valuation signals for LTS:0KF3:

  • Short-Term Debt: $ Mil
  • GF Value™: $51.03 vs. price of $11.14 (78.2% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the LTS:0KF3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Palatin Technologies Business Description

Other Exchanges PTN:USA
Address 103 Carnegie Center Drive, Suite 300, Princeton, NJ, USA, 08852
Palatin Technologies Inc. is a biopharmaceutical company that develops receptor-specific peptide therapeutics based on molecules that modulate the melanocortin receptor system. Its pipeline targets diseases with unmet medical needs, with programs focused on melanocortin-1 receptor (MC1R) agonists for inflammatory and dermatologic conditions and melanocortin-4 receptor (MC4R) agonists for metabolic and other indications. The company's most commercially advanced product is bremelanotide, an MC4R agonist marketed as Vyleesi for hypoactive sexual desire disorder in premenopausal women, which was approved by the FDA in 2019 and is licensed to a commercial partner in the United States. Palatin operates in a single business segment, life sciences, and generates revenue primarily through licensing fees, milestone payments, royalties, and collaboration agreements rather than direct product sales. The company is headquartered in Cranbury, New Jersey, and its activities are concentrated in the United States.
45GF Score

Get the complete analysis for LTS:0KF3

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.14
Price
$51.03
GF Value